Related Experiment Video

Updated: Jun 24, 2026

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages
09:57

Quantification of Monocyte Chemotactic Activity In Vivo and Characterization of Blood Monocyte Derived Macrophages

Published on: August 12, 2019

A monocyte chemoattractant protein-1 gene polymorphism is not associated with coronary artery disease in a Han

Xiaolin Zhang1, Yaling Han, Jian Kang

  • 1Department of Cardiology, Cardiovascular Research Institute, Northern Hospital, Shenyang 110016, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|April 1, 2009
PubMed

Insights

The monocyte chemoattractant protein-1 gene (MCP-1) -2518A>G polymorphism is not significantly associated with coronary artery disease (CAD) in the Han Chinese population. This study found no substantial genetic contribution of this MCP-1 variant to CAD risk.

Area of Science:

  • Genetics
  • Cardiology
  • Molecular Biology

Background:

  • Coronary artery disease (CAD) is a prevalent cardiovascular condition.
  • The monocyte chemoattractant protein-1 gene (MCP-1, CCL2) is implicated in atherogenesis.
  • Previous studies on the MCP-1 -2518A>G polymorphism and CAD have yielded conflicting results.

Purpose of the Study:

  • To investigate the association between the MCP-1 gene promoter -2518A>G polymorphism and CAD.
  • To determine if this specific genetic variation contributes to CAD susceptibility in the Han Chinese population.

Main Methods:

  • Genotyping of the MCP-1 -2518A>G polymorphism was performed.
  • The study included 502 CAD patients and 410 healthy control subjects.
  • Statistical analysis compared genotype and allele frequencies between cases and controls, with further stratification by gender, age, and clinical features.

Main Results:

  • No significant differences in genotype or allele frequencies of the MCP-1 -2518A>G polymorphism were observed between CAD patients and controls (P=0.581 and P=0.310).
  • Subgroup analyses based on gender, age, and relation to myocardial infarction also showed no significant associations.
  • The findings indicate a lack of correlation between this MCP-1 polymorphism and CAD in the studied cohort.

Conclusions:

  • The -2518A>G polymorphism in the MCP-1 gene does not appear to be a significant risk factor for CAD in the Han Chinese population.
  • This specific genetic variant of MCP-1 is unlikely to play a substantial role in the development of coronary artery disease in this ethnic group.
Abstract

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...